Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantCapital Bluecross small bowel transplant Coverage …
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy MP 9.013

    Isolated Small Bowel Transplant and Small Bowel–Liver and Multivisceral Transplant

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 9.013 alerts

    Get alerted when Policy MP 9.013 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, investigational indications, and candidate/contraindication considerations for isolated small bowel transplant and combined small bowel–liver or multivisceral transplant for adults and pediatrics dependent on long-term total parenteral nutrition (TPN). Affects Capital BlueCross members and provider prior authorization/coverage decisions.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerCapital Bluecross
    PolicyIsolated Small Bowel Transplant and Small Bowel–Liver and Multivisceral Transplant
    Policy CodePolicy MP 9.013
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewSep 10, 2024
    Next Review Date
    Key ActionObtain prior authorization for isolated small bowel, small bowel–liver, and multivisceral transplants and document TPN dependence and evidence of TPN-related complications or progressive liver failure.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    96intestinal transplants in U.S. (2021)
    30/millionSBS prevalence (U.S.)
    >3 mg/dLbilirubin threshold
    highpost-transplant risk
    case seriesevidence type
    MP 9.013policy number

    Coverage Criteria

    Isolated small bowel transplant — medically necessary

    Covered when ALL of the following are met:

    Isolated small bowel transplant criteria: 1) Intestinal failure characterized by loss of absorption and inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance; 2) Established long-term dependency on total parenteral nutrition (TPN); 3) Developing or developed severe complications due to TPN (examples include multiple/prolonged hospitalizations for TPN-related complications, repeated catheter-related sepsis, progressive liver failure, or inability to maintain venous access); 4) Documentation of patient compliance with medical management; 5) Adequate cardiopulmonary status.

    Living-donor small bowel transplant may be considered only when cadaveric intestine is not available.

    Small bowel–liver or multivisceral transplant — medically necessary

    Covered when ALL of the following are met:

    Small bowel–liver/multivisceral criteria: 1) Intestinal failure managed with long-term TPN; 2) Development of evidence of impending end-stage liver failure or progressive but reversible liver failure related to TPN; 3) Clinical assessment shows combined organ involvement making combined transplantation appropriate (choice of small bowel–liver versus multivisceral depends on etiology, native organ quality, severity of liver disease, and prior abdominal surgeries); 4) Documentation of patient compliance with medical management; 5) Adequate cardiopulmonary status.

    Multivisceral transplant is indicated when anatomic or other medical problems preclude small bowel–liver transplant.

    Retransplantation

    Covered when ALL of the following are met:

    Retransplant criteria: 1) Prior small bowel or small bowel–liver/multivisceral transplant has failed; 2) No contraindications to retransplantation (see general contraindications); 3) Candidate meets general transplant criteria and center evaluation standards (documentation of compliance, adequate cardiopulmonary status, and absence of conditions expected to make the procedure futile).

    Available evidence from case series indicates retransplantation can improve net health outcome in selected patients; retransplantation contraindicated when futile due to comorbid disease or if post-transplant care would significantly worsen comorbid conditions.

    Investigational / Not medically necessary indications

    Not covered in the following situations:

    Investigational or not medically necessary: 1) Small bowel transplant or small bowel–liver/multivisceral transplant for individuals with intestinal failure who are able to tolerate TPN (no severe TPN-related complications); 2) Small bowel transplant using living donors in situations other than when cadaveric intestine is unavailable; 3) Small bowel–liver or multivisceral transplant in situations other than those with TPN-related progressive/impending liver failure or other specified indications.

    Insufficient evidence to support benefit in these situations.

    Isolated Small Bowel Transplant

    Covered when criteria met based on evidence and selection:

    Isolated Small Bowel Transplant Coverage: Small bowel transplant may be covered for individuals with intestinal failure when transplantation is clinically appropriate; evidence is limited to case series but demonstrates meaningful improvement in net health outcome; transplantation is contraindicated if the procedure is expected to be futile due to comorbid disease or if post-transplant care will significantly worsen comorbid conditions.

    HIV infection is no longer an absolute contraindication per current guidelines and U.S. policy.

    Small Bowel–Liver and Multivisceral Transplant

    Covered when criteria met based on evidence and selection:

    Small Bowel/Liver and Multivisceral Transplant Coverage: Small bowel–liver and multivisceral transplantation may be covered for individuals with intestinal failure and impending end-stage liver failure; evidence is limited to case series but shows fairly high postprocedural survival; these procedures are contraindicated when the procedure is expected to be futile due to comorbid disease or when post-transplant care will significantly worsen comorbid conditions.

    Retransplantation of these combinations may be considered in selected patients with supportive case series data.

    Retransplantation

    Covered when criteria met for retransplantation:

    Retransplantation: Small bowel retransplantation and small bowel–liver or multivisceral retransplantation may be covered for individuals with prior graft failure when no contraindications to retransplant exist; available case series data suggest reasonably high survival in appropriately selected patients.

    Retransplantation contraindicated when futile due to comorbid disease or if post-transplant care would significantly worsen comorbid conditions.

    A small bowel transplant using a living donor is not medically necessary except when a suitable cadaveric intestine is unavailable. When cadaveric intestine is not available, living-donor small bowel transplant may be considered medically necessary only if the individual otherwise meets the policy criteria for a cadaveric intestinal transplant (documented intestinal failure with long-term TPN dependence and severe TPN-related complications).

    The existence of this medical policy does not guarantee that a given service is a covered benefit under a member's health benefit plan. Coverage, exclusions, benefit limits, and preauthorization requirements are determined by the member's specific plan language. Providers and members should consult the member's health benefit plan or contact Capital Blue Cross for benefit and preauthorization information.

    Small bowel transplant, small bowel–liver transplant, and multivisceral transplant are considered investigational / not medically necessary in situations where the individual with intestinal failure is able to tolerate total parenteral nutrition (TPN). More broadly, these procedures are investigational in all situations that do not meet the specific medical necessity criteria described in this policy because there is insufficient evidence to conclude a net health benefit in those settings.

    Candidate Criteria

    Candidate criteria for transplant

    Candidate requirements referenced in policy:

    Candidate criteria: 1) Documentation of patient compliance with medical management; 2) Adequate cardiopulmonary status; 3) Evidence of intolerance to TPN (examples include multiple/prolonged hospitalizations for TPN-related complications, repeated catheter-related sepsis, progressive liver failure, or inability to maintain venous access); 4) Presence of intestinal failure defined by loss of absorption and inability to maintain nutritional, fluid, electrolyte, or micronutrient balance.

    Candidate criteria — general considerations

    General candidate considerations noted in the policy:

    Candidate selection: 1) Candidates have intestinal failure or intestinal failure with impending end-stage liver failure; 2) Selection excludes patients for whom transplant is expected to be futile or would significantly worsen comorbid conditions; 3) HIV infection is not an absolute contraindication when HIV-specific criteria are met; 4) Centers should select candidates carefully given high post-operative risks and limited case-series evidence.

    Evidence base is primarily case series; specialized center assessment recommended.

    Contraindications

    Contraindications to transplantation include: known current malignancy (including metastatic cancer), untreated systemic infection (including chronic infections that would make immunosuppression unsafe), and recent malignancy with a high risk of recurrence. Other listed contraindications include irreversible end-stage disease not attributable to intestinal failure, systemic disease likely to be worsened by immunosuppression, history of cancer with moderate recurrence risk, and psychosocial or chemical dependency issues that would impair adherence to therapy.

    Transplantation is also contraindicated when the procedure is expected to be futile due to comorbid disease or when required post-transplant care is expected to significantly worsen existing comorbid conditions. These determinations are subject to transplant center judgment and should be made in the context of the individual patient's overall clinical status.

    A related contraindication statement reiterates that transplant should not be performed when it would be futile because of comorbid disease or when post-transplant management would materially worsen coexisting conditions. Centers should evaluate whether anticipated post-transplant immunosuppression and care needs will be detrimental to the patient's other medical conditions before approving transplantation.

    Pre-Approval Evaluation Requirements

    Documentation Required

    Document compliance, cardiopulmonary status, and TPN intolerance

    Pre-approval evaluation must document the patient’s compliance with medical management, adequate cardiopulmonary status, and evidence of intolerance to TPN (for example, multiple/prolonged hospitalizations for TPN complications, repeated catheter-related sepsis, progressive liver failure, or inability to maintain venous access).

    • Document patient compliance with medical management.
    • Document adequate cardiopulmonary status.
    • Provide specific evidence of TPN intolerance (e.g., repeated catheter-related sepsis, progressive liver failure, inability to maintain venous access).
    Note

    Standard transplant evaluations (center-performed)

    Standard transplant evaluations are assumed to be performed by the transplant center; this policy does not enumerate each routine pre-transplant evaluation step.

    • Transplant center should perform its usual candidate workup and assessments.

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required when medically necessary

    Prior authorization is required for isolated small bowel transplant, small bowel–liver transplant, and multivisceral transplant when the medical necessity criteria in this policy are met.

    • Obtain prior authorization when requesting coverage for these transplants if criteria are met.
    Prior Authorization

    Verify preauthorization per member's benefit plan

    Benefit determinations and any preauthorization requirements are governed by the member’s health benefit plan; providers should consult the member’s plan or contact Capital Blue Cross for benefit and preauthorization information.

    • Verify member coverage and preauthorization requirements with the applicable benefit plan before scheduling/transplant authorization.

    Coding Information

    Coding information section referencedmixed
    No codes listed
    Procedure codes referencedmixed
    47135Procedure code listed in policy (exact mapping in document)
    44133Procedure code listed in policy (exact mapping in document)
    44135Procedure code listed in policy (exact mapping in document)
    44136Procedure code listed in policy (exact mapping in document)
    44137Procedure code listed in policy (exact mapping in document)
    44715Procedure code listed in policy (exact mapping in document)
    44720Procedure code listed in policy (exact mapping in document)
    44721Procedure code listed in policy (exact mapping in document)
    47133Procedure code listed in policy (exact mapping in document)
    47399Unlisted procedure code referenced in policy
    1–10 of 14
    1/2
    Diagnosis codes referencedICD-10
    K72.00Acute and subacute hepatic failure without coma
    K72.01Acute and subacute hepatic failure with coma
    K72.10Chronic hepatic failure without coma
    K72.11Chronic hepatic failure with coma
    K90.49Malabsorption due to intolerance, not elsewhere classified
    K90.89Other intestinal malabsorption
    K90.9Intestinal malabsorption, unspecified
    K91.2Postsurgical malabsorption, not elsewhere classified
    T86.851Intestine transplant failure
    Total bilirubin — actionable laboratory threshold
    Total bilirubin thresholdTotal bilirubin > 3 mg/dL (laboratory level often associated with progressive, potentially irreversible liver disease in patients receiving TPN)
    ContextElevated total bilirubin in TPN-dependent patients signals progressive liver failure and is an indication to consider small bowel transplant to avoid end-stage liver disease or multivisceral transplant.
    Associated considerationsOther indications include repeated catheter-related sepsis, multiple/prolonged hospitalizations for TPN complications, or inability to maintain venous access.

    Post-Transplant Coverage and Monitoring

    Post-transplant monitoring and management — key risks
    Acute or chronic rejectionRisk of graft rejection requiring monitoring and management; acute and chronic rejection are recognized post-transplant complications.
    InfectionHigh risk of serious infection is noted as a major post-transplant concern and a leading contributor to morbidity and mortality.
    Donor-specific antibodies (DSAs)Development of DSAs can contribute to graft dysfunction and requires surveillance and potential intervention.
    Post-transplant lymphoproliferative disorder (PTLD)Lymphoproliferative disorders are listed among recognized post-transplant complications and warrant monitoring.
    Post-transplant care (general) — risks and follow-up
    Infection and graft-related complications

    Background

    Intestinal failure arises from loss of absorptive capacity of the small intestine due to surgical resection, congenital defects, or disease-associated injury. A common manifestation is short bowel syndrome, in which the remaining intestinal surface is insufficient to absorb macronutrients, fluids, electrolytes, or micronutrients, often leading to chronic dependence on total parenteral nutrition (TPN).

    Chronic TPN dependence can result in serious complications that may prompt consideration of transplantation, including repeated or prolonged hospitalizations for TPN-related issues, catheter-related bloodstream infections, progressive TPN-associated liver disease (often associated with total bilirubin levels > 3 mg/dL), and loss of adequate venous access. Small bowel, small bowel–liver, or multivisceral transplant may be appropriate for select patients with these TPN-related complications or with impending end-stage liver disease related to TPN.

    Definitions

    Short bowel syndrome / Intestinal failure — definition
    DefinitionShort bowel syndrome: inadequate absorbing surface of the small intestine due to extensive disease or surgical removal of a large portion of the small intestine.
    Functional impactMay range from isolated micronutrient malabsorption to complete intestinal failure with inability to absorb macronutrients, water, and electrolytes.
    Common etiologiesAdults: ischemia, trauma, volvulus, tumors; Children: gastroschisis, volvulus, necrotizing enterocolitis, congenital atresia.
    Multivisceral transplant — definition
    DefinitionMultivisceral transplant: transplantation that includes the small bowel and liver with one or more other gastrointestinal organs (e.g., stomach, duodenum, jejunum, ileum, pancreas, and/or colon).
    Indication

    Center Requirements and Program Access

    Documentation Required

    Center judgment governs candidacy and contraindications

    Transplant candidacy determinations and assessment of contraindications are made by the transplant center; outcomes and candidate selection rely on specialized center expertise.

    • Centers retain clinical judgment for candidate selection and contraindication evaluation.
    Note

    Blue Distinction Centers for Transplant (BDCT) referenced

    The policy references Blue Distinction Centers for Transplant (BDCT) as a program to provide access to leading transplant centers.

    • Consider BDCT designation when selecting a transplant center for referral.
    Note

    BDCT program referenced (duplicate)

    Policy reiterates the BDCT program as a resource for access to leading transplant centers (duplicate reference).

    Revision History

    2024references_updatedLatest

    References updated through 2024 as part of recent policy maintenance and literature review.

    2023consensus_review

    Consensus review conducted (policy statements unchanged); administrative updates including coding review noted.

    2020-05-21consensus_review
    Policy Summary
    PayerCapital Bluecross
    PolicyIsolated Small Bowel Transplant and Small Bowel–Liver and Multivisceral Transplant
    Policy CodePolicy MP 9.013
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewSep 10, 2024
    Next Review Date
    Key ActionObtain prior authorization for isolated small bowel, small bowel–liver, and multivisceral transplants and document TPN dependence and evidence of TPN-related complications or progressive liver failure.
    SourceLink
    On This Page
    Coverage CriteriaCandidate CriteriaContraindicationsPre-Approval Evaluation RequirementsProvider Actions and RequirementsCoding InformationPost-Transplant Coverage and MonitoringBackgroundDefinitionsCenter Requirements and Program AccessRevision History
    Note

    Pre-transplant workup details not specified here

    The policy references standard pre-transplant workup implicitly but does not provide detailed step-by-step evaluation protocols in this document.

    • Consult center guidelines and cited OPTN/society references for detailed pre-transplant evaluation procedures.
    Prior Authorization

    Reference policy MP 9.013 for prior authorization

    Consult policy MP 9.013 for coverage determinations when obtaining prior authorization for isolated small bowel and multivisceral transplants.

    • Reference MP 9.013 in prior authorization submissions and discussions with the plan.
    Documentation Required

    Use cadaveric intestine first; living-donor only if unavailable

    Document consideration of cadaveric intestine as the first option; living-donor small bowel transplant should be considered only when cadaveric intestine is not available and the patient meets the policy criteria for transplant.

    • Record that cadaveric organ availability was assessed and documented before pursuing living-donor transplant.
    Step Therapy

    No step therapy specified

    The policy does not define any step-therapy sequence for intestinal or multivisceral transplant; no step therapy is specified in this document.

    • Do not assume an internal step-therapy ladder is required based on this policy excerpt.
    Note
    Documentation Required

    Document intestinal failure etiology, TPN dependence, and compliance

    Include documentation of the intestinal failure etiology and the patient’s inability to maintain nutrition without TPN, and evidence of compliance with medical management as part of the authorization record.

    • Document cause of intestinal failure (e.g., short bowel syndrome, congenital defect).
    • Document long-term dependence on TPN and specific TPN-related complications.
    • Document adherence to medical management.
    Billing Rule

    Include coding and consult benefit plan

    Provide appropriate procedure and diagnosis codes with authorization requests and consult the member’s benefit plan for coverage determinations; coding lists are included in the policy but coverage is determined by benefit language.

    • Include relevant CPT/HCPCS and ICD-10 codes from the policy coding section with submissions.
    • Confirm coverage and reimbursement details with the member's plan.
    Documentation Required

    Include referenced OPTN/clinical literature in documentation

    Cite the policy references and clinical literature (OPTN, association position statements, and specialty society guidance) in clinical documentation to support transplant coverage requests.

    • Attach relevant literature or guideline excerpts referenced in the policy to the authorization request when applicable.
    Denial Risk

    Absolute contraindications that may trigger denial

    Known current malignancy, untreated systemic infection, recent malignancy with high risk of recurrence, psychosocial conditions or chemical dependency affecting adherence, and other specified irreversible end-stage diseases are listed potential contraindications that may lead to denial of transplant coverage.

    • Known current malignancy (including metastatic cancer).
    • Untreated systemic infection (including chronic infection).
    • Recent malignancy with high risk of recurrence.
    • Other irreversible end-stage disease not attributed to intestinal failure.
    • Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.
    Denial Risk

    Contraindications based on futility or worsened comorbidity

    Transplantation is contraindicated and may be denied when the procedure is expected to be futile because of comorbid disease or when post-transplant care is expected to significantly worsen the patient’s comorbid conditions.

    • Assess and document whether comorbid conditions make the procedure futile or post-transplant care unsafe.
    Billing Rule

    Administrative/coding review risk — verify codes

    Policy history notes that coding was reviewed with no coding changes; absence of explicit coding changes in recent reviews may lead to administrative denials if providers use codes not referenced in the policy—verify codes against the policy coding section.

    • Confirm codes used for billing are those referenced in the policy and current payer code lists.
    • Be aware administrative history indicates coding was reviewed but not changed.
    Post-transplant morbidity and mortality risks are high, with infection highlighted as a notable risk after small bowel and multivisceral transplants.
    Rejection and immunologic complicationsAcute and chronic rejection and development of donor-specific antibodies are important causes of post-transplant morbidity.
    Graft-versus-host disease and renal dysfunctionGraft-versus-host disease and renal dysfunction are listed among potential post-transplant complications.
    Need for specialized follow-upPost-transplant care requires specialized center management and long-term surveillance; centers should follow relevant guidelines and literature.
    Indicated when anatomic or other medical problems preclude a small bowel–liver transplant and combined organ replacement is required.
    Procedural considerationsType of transplantation depends on etiology of intestinal failure, native organ quality, liver disease severity, and prior abdominal surgeries.
    INTestinal FAILURE — definition
    Definition (concise)INTestinal FAILURE: loss of absorptive capacity of the small bowel secondary to severe primary gastrointestinal disease or surgically induced short bowel syndrome.
    Clinical consequenceLeads to inability to maintain macronutrient, fluid, electrolyte, or micronutrient balance and may require long-term TPN.
    Relation to transplantIntestinal failure is the primary condition prompting consideration of small bowel, small bowel–liver, or multivisceral transplantation.
    MULTIVISCERAL TRANSPLANT — definition (alternate)
    Definition (alternate wording)MULTIVISCERAL TRANSPLANT: transplantation of the small bowel and liver in conjunction with other gastrointestinal organs; used when combined organ replacement is required.
    Clinical useEmployed when combined organ involvement or anatomic issues make isolated small bowel–liver transplant inappropriate or impossible.
    Potential complicationsComplications include acute/chronic rejection, donor-specific antibodies, infection, lymphoproliferative disorder, graft-versus-host disease, and renal dysfunction.
    TPN — definition
    DefinitionTPN (total parenteral nutrition): intravenous provision of dextrose, amino acids, emulsified fats, trace elements, vitamins, and minerals for patients unable to assimilate adequate nutrition orally.
    Role in intestinal failureTPN is used long-term in patients with intestinal failure but is associated with complications such as catheter-related infections and progressive liver disease.
    When transplant is consideredDevelopment of severe TPN-related complications (e.g., repeated catheter-related sepsis, progressive liver failure, inability to maintain venous access) may prompt consideration of transplant.
    BLUE DISTINCTION CENTERS FOR TRANSPLANT (BDCT)
    Program descriptionBLUE DISTINCTION CENTERS FOR TRANSPLANT (BDCT) is a cooperative effort of Blue Cross and Blue Shield Plans and participating institutions to provide patients access to leading transplant centers through a coordinated program.
    PurposeDesigned to streamline transplant management and improve access to specialized transplant centers for patients needing transplantation.
    RelevancePolicy references BDCT as a program for accessing leading transplant centers when center expertise affects candidacy and outcomes.
    Multivisceral transplant — referenced (fallback)
    Fallback definitionMultivisceral transplant (referenced): combined transplantation including small bowel and liver with other gastrointestinal organs; in this document it is referenced via cited literature and OPTN/policy sources rather than a detailed standalone definition.
    Guidance sourceRefer to OPTN, association position statements, and specialty society guidance cited in the policy for detailed definitions and indications.
    When to consultConsult full policy references and center-specific protocols for operative composition and candidate selection when multivisceral transplant is being considered.
    • BDCT is a cooperative program of Blue Cross and Blue Shield Plans to identify leading transplant centers.

    Consensus review completed with no clinical policy statement changes; policy reformatted and HIV guidelines and references updated; coding reviewed.